Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinische Wochenschrift
Erschienen in:

01.06.2016 | original article

Crizotinib-induced toxicity in an experimental rat model

verfasst von: Ozge Gumusay, MD, Guldal Esendagli-Yilmaz, Aytug Uner, Bulent Cetin, Suleyman Buyukberber, Mustafa Benekli, Mustafa N. Ilhan, Ugur Coskun, Ozlem Gulbahar, Ahmet Ozet

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 11-12/2016

Einloggen, um Zugang zu erhalten

Summary Aim Methods Results Conclusion

The aim of the present study was to evaluate the effect of crizotinib on visceral organs in an experimental rat model.
Eighteen Wistar albino rats were divided into three groups: experimental toxicity was induced with crizotinib (10 mg/kg) administered for 28 days (Group 1), 42 days (Group 2) orally by gavage. Control group received only distilled water. Rats in Group 1 and Group 2 were sacrificed after the collection of blood and tissue samples on the 28th and 42nd days, respectively.
Subjects in Group 1 and Group 2 had abnormal histology mainly in lung and liver. There were intraalveolar hemorrhage in lungs; mild portal inflammation, perivenular focal and confluent necrosis in liver; inflammatory reaction in renal pelvis and periureteral areas, and focal pancreatitis in pancreas.
This study is the first to evaluate the histopathological features of toxicity of crizotinib in a rat model.
Vorheriger Artikel Mechanism of nonylphenol-induced neurotoxicity in F1 rats during sexual maturity
Nächster Artikel Detection of Epstein–Barr virus in inflammatory pseudotumour of the spleen: a case report
Literatur
1.
Jemal A, Bray F, Center MM, Ferlay J, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMed
2.
3.
Collins LG, Haines C, Perkel R, et al. Lung cancer: diagnosis and management. Am Fam Physician. 2007;75(1):56–63.PubMed
4.
Alberts WM. Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest. 2007;132(3 Suppl):1S–19S.CrossRefPubMed
5.
Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.CrossRefPubMed
6.
Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500.CrossRefPubMed
7.
8.
Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–6.CrossRefPubMed
9.
Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011;6(5):942–6.CrossRefPubMed
10.
Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13(10):1011–9.CrossRefPubMedPubMedCentral
11.
Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–94.CrossRefPubMed
12.
Stahel RA, Rosell R, Thatcher N, Soria JC. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Eur J Cancer. 2012;48(7):961–73.CrossRefPubMed
13.
Crinò L, Kim D, Riely GJ, et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol. 2011;29 (suppl; abstr 7514).
14.
Smith EB, Goulet L, Walker GS, et al. Metabolism and excretion of Crizotinib in rats and dogs. 17th North American Regional International society for the study of xenobiotics Meeting. (P82).
15.
16.
Qian H, Gao F, Wang H, et al. The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials. BMC Cancer. 2014;14:683.CrossRefPubMedPubMedCentral
17.
Loriot Y, Perlemuter G, Malka D, et al. Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol. 2008;5(5):268–78.CrossRefPubMed
18.
Demirci U, Buyukberber S, Yılmaz G, et al. Hepatotoxicity associated with lapatinib in an experimental rat model. Eur J Cancer. 2012;48(2):279–85.CrossRefPubMed
19.
Ripault MP, Pinzani V, Fayolle V, et al. Crizotinib-induced acute hepatitis: first case with relapse after reintroduction with reduced dose. Clin Res Hepatol Gastroenterol. 2013;37(1):e21–3.CrossRefPubMed
20.
Sato Y, Fujimoto D, Shibata Y, et al. Fulminant hepatitis following crizotinib administration for ALK-positive non-small-cell lung carcinoma. Jpn J Clin Oncol. 2014;44(9):872–5.CrossRefPubMed
21.
Pariente A, Etcharry F, Cales V, et al. Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour. Eur J Gastroenterol Hepatol. 2006;18(7):785–7.CrossRefPubMed
22.
Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99(7):2310–4.CrossRefPubMed
23.
Ono A, Takahashi T, Oishi T, et al. Acute lung injury with alveolar hemorrhage as adverse drug reaction related to crizotinib. J Clin Oncol. 2013;31(26):e417–9.CrossRefPubMed
24.
25.
Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2006;24:2549–56.CrossRefPubMed
26.
Higenbottam T, Kuwano K, Nemery B, et al. Understanding the mechanisms of drug-associated interstitial lung disease. Br J Cancer. 2004;91(Suppl 2):S31–7.CrossRefPubMedPubMedCentral
27.
Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet. 2003;361(9352):137–9.CrossRefPubMed
28.
29.
Tirumani SH, Jagannathan JP, Shinagare AB, et al. Acute pancreatitis associated with molecular targeted therapies: a retrospective review of the clinico-radiological features, management and outcome. Pancreatology. 2013;13(5):461–7.CrossRefPubMed
30.
31.
Martín Martorell P, Huerta Alvaro M, Solís Salguero MA, et al. Crizotinib and renal insufficiency: a case report and review of the literature. Lung Cancer. 2014;84(3):310–3.CrossRefPubMed
32.
Brosnan EM, Weickhardt AJ, Lu X, et al. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer. 2014;120(5):664–74.CrossRefPubMed
Metadaten
Titel
Crizotinib-induced toxicity in an experimental rat model
verfasst von
Ozge Gumusay, MD
Guldal Esendagli-Yilmaz
Aytug Uner
Bulent Cetin
Suleyman Buyukberber
Mustafa Benekli
Mustafa N. Ilhan
Ugur Coskun
Ozlem Gulbahar
Ahmet Ozet
Publikationsdatum
01.06.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 11-12/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-016-0984-y

Weitere Artikel der Ausgabe 11-12/2016

Tracheostomy is associated with decreased hospital mortality after moderate or severe isolated traumatic brain injury

  • Open Access
  • original article

Esophageal squamous papillomatosis

  • images in clinial medicine

Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial infarction

  • Open Access
  • review article

Mechanism of nonylphenol-induced neurotoxicity in F1 rats during sexual maturity

  • original article

Percutaneous instillation of physiological saline solution for the treatment of femoral pseudoaneuryms

  • original article

Insulin adsorption by infusion sets in the setting of treatment of hyperkalaemia

  • letter to the editor